- Home
- SCNX vs BRTX Comparison
SCNX vs BRTX Comparison
Compare SCNX & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCNX
- BRTX
- Stock Information
- Founded
- SCNX 2010
- BRTX 1997
- Country
- SCNX United States
- BRTX United States
- Employees
- SCNX N/A
- BRTX N/A
- Industry
- SCNX Other Pharmaceuticals
- BRTX Managed Health Care
- Sector
- SCNX Health Care
- BRTX Health Care
- Exchange
- SCNX Nasdaq
- BRTX Nasdaq
- Market Cap
- SCNX 14.0M
- BRTX 11.3M
- IPO Year
- SCNX 2020
- BRTX N/A
- Fundamental
- Price
- SCNX $8.10
- BRTX $1.41
- Analyst Decision
- SCNX
- BRTX Strong Buy
- Analyst Count
- SCNX 0
- BRTX 1
- Target Price
- SCNX N/A
- BRTX $18.00
- AVG Volume (30 Days)
- SCNX 18.2K
- BRTX 33.9K
- Earning Date
- SCNX 11-06-2024
- BRTX 11-12-2024
- Dividend Yield
- SCNX N/A
- BRTX N/A
- EPS Growth
- SCNX N/A
- BRTX N/A
- EPS
- SCNX 3.55
- BRTX N/A
- Revenue
- SCNX N/A
- BRTX $377,000.00
- Revenue This Year
- SCNX $1,085.75
- BRTX $598.90
- Revenue Next Year
- SCNX N/A
- BRTX $162.81
- P/E Ratio
- SCNX $3.46
- BRTX N/A
- Revenue Growth
- SCNX 166.67
- BRTX 189.55
- 52 Week Low
- SCNX $3.69
- BRTX $1.03
- 52 Week High
- SCNX $44.56
- BRTX $3.67
- Technical
- Relative Strength Index (RSI)
- SCNX N/A
- BRTX 38.90
- Support Level
- SCNX N/A
- BRTX $1.21
- Resistance Level
- SCNX N/A
- BRTX $1.78
- Average True Range (ATR)
- SCNX 0.00
- BRTX 0.17
- MACD
- SCNX 0.00
- BRTX -0.02
- Stochastic Oscillator
- SCNX 0.00
- BRTX 34.54
About SCNX Scienture Holdings Inc. Common Stock
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.
About BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.